Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

napabucasin (BBI608)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Sumitomo Pharma

Drug class:

STAT3 inhibitor

Related drugs:

MSI-H/dMMR	Prostate Cancer	MSI-H/dMMR	Prostate Cancer	pembrolizumab + BBI608 Sensitive: C3 – Early Trials pembrolizumab + BBI608 Sensitive : C3	pembrolizumab + BBI608 Sensitive: C3 – Early Trials pembrolizumab + BBI608 Sensitive : C3
MUC1 overexpression	Pancreatic Ductal Adenocarcinoma	MUC1 overexpression	Pancreatic Ductal Adenocarcinoma	BBI608 Sensitive: D – Preclinical BBI608 Sensitive : D	BBI608 Sensitive: D – Preclinical BBI608 Sensitive : D
STAT3 expression	Gastric Cancer	STAT3 expression	Gastric Cancer	BBI608 Sensitive: D – Preclinical BBI608 Sensitive : D	BBI608 Sensitive: D – Preclinical BBI608 Sensitive : D
NFKB1 expression	Gastric Cancer	NFKB1 expression	Gastric Cancer	BBI608 Sensitive: D – Preclinical BBI608 Sensitive : D	BBI608 Sensitive: D – Preclinical BBI608 Sensitive : D